Sophiris Bio's (SPHS) Phase 3 Study of PRX302 Met Primary Endpoint in BPH
Tweet Send to a Friend
Sophiris Bio Inc. (NASDAQ: SPHS) announced final results from its Phase 3 "PLUS-1" study of PRX302 as a treatment for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
